W. R. Wolfe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
W. R. Wolfe has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
D. B. Dickinson
Botswana-Harvard School of Public Health Partnership , Gaborone , Botswana
1 shared publicationD. R. Bangsberg
University of California , San Francisco
1 shared publicationI. Thior
Botswana-Harvard School of Public Health Partnership , Gaborone , Botswana
1 shared publicationJ. M. Makhema
Botswana-Harvard School of Public Health Partnership , Gaborone , Botswana
1 shared publicationK. F. Mompati
Botswana-Harvard School of Public Health Partnership , Gaborone , Botswana
1 shared publicationR. G. Marlink
Harvard School of Public Health AIDS Initiative , Boston , USA
1 shared publication
Latest Publications
- 1 November 2006
- Published by Taylor & Francis in AIDS Care
- Vol. 18 (8) , 931-933
Effects of HIV-related stigma among an early sample of patients receiving antiretroviral therapy in Botswana
Botswana, with its estimated HIV prevalence of 37%, instituted a policy of universal access to antiretroviral therapy (ART) in 2002. Initial enrolment lagged behind expectations, with a shortfall in voluntary testing that observers have attributed to HIV-related stigma – although there are no published data on stigma among HIV-positive individuals in Botswana. We interviewed 112 patients receiving ART in 2000, finding evidence of pervasive stigma in patterns of disclosure, social sequelae, and delays in HIV testing. Ninety-four percent of patients reported keeping their HIV status secret from their community, while 69% withheld this information even from their family. Twenty-seven percent of patients said that they feared loss of employment as a result of their HIV status. Forty percent of patients reported that they delayed getting tested for HIV; of these, 51% cited fear of a positive test result as the primary reason for delay in seeking treatment, which was often due to HIV-related stigma. These findings suggest that success of large-scale national ART programmes will require initiatives targeting stigma and its social, economic and political correlates.
- 1 November 2006
- Published by Taylor & Francis in AIDS Care
- Vol. 18 (8) , 931-933
Effects of HIV-related stigma among an early sample of patients receiving antiretroviral therapy in Botswana
Botswana, with its estimated HIV prevalence of 37%, instituted a policy of universal access to antiretroviral therapy (ART) in 2002. Initial enrolment lagged behind expectations, with a shortfall in voluntary testing that observers have attributed to HIV-related stigma – although there are no published data on stigma among HIV-positive individuals in Botswana. We interviewed 112 patients receiving ART in 2000, finding evidence of pervasive stigma in patterns of disclosure, social sequelae, and delays in HIV testing. Ninety-four percent of patients reported keeping their HIV status secret from their community, while 69% withheld this information even from their family. Twenty-seven percent of patients said that they feared loss of employment as a result of their HIV status. Forty percent of patients reported that they delayed getting tested for HIV; of these, 51% cited fear of a positive test result as the primary reason for delay in seeking treatment, which was often due to HIV-related stigma. These findings suggest that success of large-scale national ART programmes will require initiatives targeting stigma and its social, economic and political correlates.